# Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

> **NCT04158505** · — · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 3000 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **OTHER:** non-interventional

## Key facts

- **NCT ID:** NCT04158505
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-28
- **Primary completion:** 2021-11-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158505, "Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04158505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*